INVA - NASDAQ
Innoviva, Inc.
$21.70
+0.88%Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
At a Glance
Live SnapshotInnoviva, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Flat FCF growth. Stable but not expanding—monitor for signs of business maturity or temporary headwinds.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Solid cash generation: Positive free cash flow with reasonable earnings quality provides financial flexibility for growth investments, debt reduction, or shareholder returns.
Innoviva, Inc. Cash Flow Statement
INVA • NASDAQ
| Innoviva, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
271.2M | 23.4M | 179.7M | 220.3M | 368.8M | 293.8M | 191M | 406.3M | 134.3M | 59.5M | -18.8M | -168.5M | -170.7M | -18.5M | -115.3M | -83.9M | -85.3M | -93.6M | -160M | -166M | |
40.2M | 39.9M | 35.7M | 19.5M | 13.8M | 0.0 | 13.9M | 13.9M | 14M | 14M | 13.9M | 12.2M | 8.2M | 7.3M | 7.6M | 6.3M | 5.5M | 7M | 4.1M | 4.2M | |
43.8M | -12.6M | 4.4M | 25M | 76.4M | 60.4M | 41.9M | -196.1M | 7.2M | -2.4M | -637K | 5.5M | 1.4M | 0.0 | 0.0 | 33K | 0.0 | 0.0 | 0.0 | 0.0 | |
9.5M | 6.4M | 5.8M | 7.3M | 2M | 1.7M | 2.1M | 3.2M | 9.8M | 8.3M | 6.9M | 27.4M | 25.7M | 23.8M | 24.9M | 19M | 20M | 18M | 22.5M | 21.8M | |
-143.6M | 138.6M | -59.8M | -77.3M | -80.4M | -28.5M | 5.6M | 12.9M | 11.9M | 1.2M | 24.9M | 28.4M | 1.4M | 187K | 16K | 41K | -13K | 18.1M | 23M | 22.6M | |
(0.0) | (11.8M) | (0.0) | (53.9M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-24.2M | -6.9M | -24.8M | 6.9M | -16.9M | -14.3M | 3.1M | -16.8M | -28.3M | -22M | -16.9M | -30.3M | 5.8M | -140.7M | -5.5M | -16.7M | 1.7M | -31.3M | 28.5M | 34.5M | |
196.9M | 188.7M | 141.1M | 201.7M | 363.8M | 313.1M | 257.5M | 223.5M | 141.7M | 61M | 10.1M | -130.7M | -129.6M | -128M | -88.3M | -75.1M | -58.1M | -99.9M | -104.4M | -104.8M | |
INVESTING ACTIVITIES | ||||||||||||||||||||
-1.1M | -270K | -411K | -67K | -1.3M | -13K | -12K | (0.0) | (0.0) | -278K | -7K | -689K | -87.7M | -2.6M | -3.6M | -861K | -744K | -1M | -9.8M | -5.7M | |
(0.0) | (0.0) | (0.0) | -33.2M | -235.8M | -102.9M | (18M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -85M | (0.0) | (0.0) | (12K) | (0.0) | (103K) | (0.0) | (0.0) | |
(14.4M) | -135.4M | -138.9M | -23.4M | (22.3M) | -298.1M | -231.9M | -71.9M | -67.6M | -95.7M | -86.5M | -276.9M | -410.4M | -330.5M | -301.6M | -183.9M | -123.5M | -371.6M | -93.3M | -191M | |
28.2M | 75.8M | 72.5M | 56.6M | 279.5M | 86M | 213.9M | 75.4M | 44.4M | 91.4M | 245.7M | 346.6M | 278.5M | 274.6M | 248.8M | 143.9M | 123.1M | 304.9M | 212.6M | 178.5M | |
-929K | -3.9M | 0.0 | -56.6M | -21M | 0.0 | -18M | 3.5M | -23.2M | -4.3M | 159.2M | -134M | -84.9M | 160K | 575K | 569K | 2.9M | 384K | 1.2M | -443K | |
(40.5M) | -63.8M | -66.8M | -56.6M | (43.7M) | -314.9M | -18M | (3.5M) | -23.2M | -4.6M | (159.2M) | -65.1M | -219.6M | -58.3M | -55.8M | -40.3M | (1.7M) | -67.4M | (110.6M) | -18.6M | |
FINANCING ACTIVITIES | ||||||||||||||||||||
8.6M | -13.5M | -75.6M | -8.2M | -393M | 344K | 538K | -1.9M | -99.2M | -78.8M | -19.6M | 48.9M | 153M | 236.4M | 25.8M | 231.4M | 11.7M | 6.5M | 7.9M | 147.2M | |
-25K | 0.0 | -96.2M | 66.4M | 0.0 | 0.0 | -13.8M | -230M | -63.7M | -18.4M | 0.0 | 434.7M | 281.6M | -69K | -206K | -184K | -131K | 166.6M | -88K | -1.3M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -11K | -80K | -281K | -960K | -87.3M | -57M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-4.7M | -14.9M | -75.8M | -8.6M | -394.2M | -92K | -89K | -3.1M | -99.6M | -79.2M | -27.8M | -5.7M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
0.0 | 0.0 | 0.0 | -113.4M | -59.5M | -30.1M | -10.6M | -6M | 458K | 0.0 | 8.2M | -277.5M | -36.8M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
8.6M | -13.5M | -171.8M | -55.6M | -452.5M | -29.8M | -23.8M | -238M | -163.2M | -97.6M | -106.9M | 149.1M | 397.8M | 236.3M | 25.6M | 231.2M | 11.6M | 173.1M | 7.8M | 146M | |
CASH FLOW SUMMARY | ||||||||||||||||||||
246M | 111.5M | -97.5M | 89.5M | -45M | -31.6M | 215.7M | -10.9M | -44.7M | -41.2M | 62.4M | -46.7M | 48.7M | 50.1M | -118.6M | 115.8M | -44.7M | 5.8M | 14M | 22.6M | |
305M | 193.5M | 291M | 201.5M | 246.5M | 278.1M | 62.4M | 73.3M | 118M | 159.2M | 96.8M | 143.5M | 94.8M | 44.8M | 163.3M | 47.5M | 92.3M | 86.4M | 72.4M | 49.8M | |
550.9M | 305M | 193.5M | 291M | 201.5M | 246.5M | 278.1M | 62.4M | 73.3M | 118M | 159.2M | 96.8M | 143.5M | 94.8M | 44.8M | 163.3M | 47.5M | 92.3M | 86.4M | 72.4M | |
195.8M | 188.4M | 140.7M | 201.7M | 362.5M | 313.1M | 257.4M | 223.5M | 141.7M | 60.7M | 10.1M | -131.4M | -217.3M | -130.5M | -92M | -76M | -58.8M | -100.9M | -114.2M | -110.5M |
SEC Filings
INVA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 18, 2026 | May 12, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 04, 2026 | May 04, 2026 | 2026 | |
10-K/A 10-K/A 2025 FY (Amended) FY | March 27, 2026 | December 31, 2025 | 2025 | |
DEF 14A DEF 14A 2026 N/A | March 24, 2026 | March 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 25, 2026 | February 25, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 25, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 05, 2025 | November 05, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 05, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your INVA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.